Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
复制标题
淋巴因子激活的杀伤细胞、白细胞介素 2 和特异性单克隆抗体联合治疗对已确定的 B16 黑色素瘤肺转移的影响。
作者：
A. Eisenthal;Robert B. Cameron;I. Uppenkamp;S. A. Rosenberg
我们之前的研究表明，用特异性抗b16黑色素瘤单克隆抗体（Mab）治疗C57BL/6小鼠可显著减少已建立的肝转移数量。在本文中，我们表明，当用Mab治疗同时患有肝和肺微转移的小鼠时，肝转移的数量减少了72-98%，而肺转移的数量没有受到影响。与治疗肝转移的结果相反，当重组白细胞介素2同时给予或在高剂量重组白细胞介素2引发后，单抗和重组白细胞介素2治疗B16黑色素瘤肺转移不成功。相反，当抗b16单抗治疗与C3H淋巴因子激活的杀伤细胞（LAK）联合使用时，LAK细胞的抗肿瘤功效显著增强，LAK细胞显示出抗体依赖性细胞毒性（ADCC）活性。C57BL/6 LAK细胞表现出较低的ADCC活性，无法介导类似的效果，这表明ADCC样机制参与了这种治疗。C3H LAK细胞的作用显然不是异体细胞给药的结果，因为新鲜的C3H脾细胞与Mab一起给药时对肺转移没有影响。这些发现表明，特异性抗肿瘤单抗不仅可以影响已建立的肝转移瘤，而且当与介导ADCC活性的LAK细胞结合时，也可以增强肺转移瘤的根除。
We have previously shown that treatment of C57BL/6 mice with specific anti-B16 melanoma monoclonal antibody (Mab) significantly reduced the number of established liver metastases. In this paper we show that when treatment with Mab was applied to mice bearing both liver and lung micrometastases, the number of liver metastases was reduced by 72-98%, whereas no effect was seen on the number of lung metastases. In contrast to results obtained when treating liver metastases, treatment of B16 melanoma lung metastases with Mab and recombinant interleukin 2 was unsuccessful when recombinant interleukin 2 was given concomitantly or after priming with high doses of recombinant interleukin 2. In contrast, when therapy with anti-B16 Mab was combined with the administration of C3H lymphokine-activated killer (LAK) cells, which were shown to exhibit antibody dependent cellular cytotoxicity (ADCC) activity, a significant enhancement in the antitumor efficacy of LAK cells was seen. The inability of C57BL/6 LAK cells, which exhibited low if any ADCC activity to mediate a similar effect, suggested that an ADCC-like mechanism was involved in this therapy. The effect of C3H LAK cells was apparently not the result of administration of allogeneic cells, since fresh C3H splenocytes had no effect on lung metastases when given together with Mab. These findings demonstrate the potential of specific antitumor Mab to affect not only established liver metastases but, when combined with LAK cells that mediate ADCC activity to enhance the eradication of lung metastases as well.
登录
查看更多内容
Interleukin-2 增强单克隆抗体介导的针对人黑色素瘤的细胞毒性。
影响因子：
11.2
作者：
Munn,DH;Cheung,NK
通讯作者：
Cheung,NK
DOI：
10.1073/pnas.81.11.3506
发表时间：
1984-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
ADAMS, DO;HALL, T;KOPROWSKI, H
通讯作者：
KOPROWSKI, H
使用单克隆抗体和 IL 2 治疗小鼠 B 细胞淋巴瘤。
DOI：
--
发表时间：
1987
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Berinstein,N;Levy,R
通讯作者：
Levy,R
DOI：
--
发表时间：
1985
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Weinhold,KJ;Bolognesi,DP;Matthews,TJ
通讯作者：
Matthews,TJ
DOI：
10.1073/pnas.79.15.4761
发表时间：
1982-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
HERLYN, D;KOPROWSKI, H
通讯作者：
KOPROWSKI, H